Drug Trial Radar · NCT05722886
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
825
Planned (sponsor's estimate)
Start
Mar 1, 2023
Primary completion
Oct 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- Cancer Research UKAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; Novartis Pharmaceuticals
- First posted
- Feb 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Patients must have a cancer with an identified mutation. This could be found during routine testing or as part of another research programme. The DETERMINE trial will recruit adults, teenagers and children. If a drug is found to benefit a new patient group, the study team will work with the NHS and the Cancer Drugs Funds to see if these drugs can be available for patients in the future. This clinicaltrials.gov record refers to the Overall Trial Protocol (Master Screening Record), additional records will be added to clinicaltrials.gov for each treatment arm.
Conditions
- Haematological Malignancy
- Solid Tumour
Interventions
AlectinibDrug
Adult patients will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily. Paediatric patients with a body weight ≥40 kg and who are able to swallow the capsules will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.
AtezolizumabDrug
Adult patients will receive 1200 mg of atezolizumab intravenously every 21 days. Paediatric patients will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days. Patients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.
EntrectinibDrug
Adult and paediatric patients with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day). Paediatric patients with BSA \<1.51 m\^2 will receive a dose adjusted for BSA. Each cycle of treatment will consist of 28 days and patients may continue until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.
Trastuzumab in combination with pertuzumabDrug
The initial loading dose of trastuzumab is 8 mg/kg body weight followed thereafter by a maintenance dose of 6 mg/kg body weight administered intravenously every 21 days. The initial loading dose of pertuzumab is 840 mg followed thereafter by a maintenance dose of 420 mg administered intravenously every 21 days. Paediatric patients will receive a dose of pertuzumab adjusted by body weight. Patients may continue until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.
Vemurafenib in combination with cobimetinibDrug
Patients will receive vemurafenib at a dose of 960 mg (four tablets of 240 mg) orally on a twice daily schedule throughout a 28-day cycle. Patients will receive cobimetinib at a dose of 60 mg (three tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break. Patients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.
CapmatinibDrug
Patients will receive capmatinib orally at a daily dose of 800 mg consisting of 400 mg (two 200 mg tablets) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.
Dabrafenib in combination with trametinibDrug
Adult patients (≥18 years) will receive dabrafenib at a dose of 150 mg (two 75 mg tablets) twice daily (total daily dose 300 mg). Paediatric patients (1 to \<12 years) will receive dabrafenib dose adjusted by body weight as 10 mg dispersible tablets orally twice daily. Paediatric patients (≥12 years) and TYA patients (16 to \<18 years) will have the option to receive adult or paediatric dosing. Adult patients will receive trametinib at a daily dose of 2 mg (one 2 mg tablet) orally once daily (total daily dose 2 mg). Paediatric patients receive trametinib at a dose adjusted by body weight as 0.05 mg/m\^2 powder for oral solution twice daily. Paediatric patients (≥12 years) and TYA patients (16 to \<18 years) will have the option to receive adult or paediatric dosing. Each cycle of treatment will consist of 28 days. Patients may continue until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients who consent to each arm.Time frame: Up to 5 years.
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Belfast City Hospital
Belfast, United Kingdom · Recruiting
University Hospital Birmingham
Birmingham, United Kingdom · Recruiting
Birmingham Children's Hospital
Birmingham, United Kingdom · Not yet recruiting
Bristol Royal Hospital for Children
Bristol, United Kingdom · Recruiting
Bristol Haematology and Oncology Centre
Bristol, United Kingdom · Recruiting
Addenbrooke's Hospital
Cambridge, United Kingdom · Recruiting
Velindre Cancer Centre
Cardiff, United Kingdom · Recruiting
Cardiff Children's Hospital
Cardiff, United Kingdom · Recruiting
Western General Hospital
Edinburgh, United Kingdom · Recruiting
The Beatson Hospital
Glasgow, United Kingdom · Recruiting
Royal Hospital for Children Glasgow
Glasgow, United Kingdom · Recruiting
Leicester Royal Infirmary
Leicester, United Kingdom · Recruiting
Alder Hey Hospital
Liverpool, United Kingdom · Recruiting
University College London Hospital
London, United Kingdom · Recruiting
Guy's Hospital
London, United Kingdom · Recruiting
Great Ormond Street Hospital
London, United Kingdom · Recruiting
Royal Manchester Children's Hospital
Manchester, United Kingdom · Recruiting
The Christie Hospital
Manchester, United Kingdom · Recruiting
Clatterbridge Cancer Centre
Metropolitan Borough of Wirral, United Kingdom · Recruiting
Great North Children's Hospital
Newcastle, United Kingdom · Recruiting
Freeman Hospital
Newcastle, United Kingdom · Recruiting
Churchill Hospital
Oxford, United Kingdom · Recruiting
John Radcliffe Hospital
Oxford, United Kingdom · Recruiting
Weston Park Hospital
Sheffield, United Kingdom · Recruiting
Sheffield's Children's Hospital
Sheffield, United Kingdom · Recruiting
Southampton General Hospital
Southampton, United Kingdom · Recruiting
The Royal Marsden Hospital
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.